Small companies lead the I-O class of Cancer Therapies
ACCESSWIRE - Fri Aug 08, 7:02AM CDT
Los Angeles, CA / August 8, 2014 / Tumor cells, tending to persist after treatment, lead to remission and have been a bane to cancer researchers and doctors for decades. Only recently, immuno-oncology, labeled 'I-O' first by Bristol-Myers Squibb Company (NYSE:BMY) has emerged to become a new class of cancer medicines that may someday take a meaningful place alongside chemotherapy, surgery, and radiation.
CLSN: 2.41 (+0.09), NWBO: 6.07 (+0.13), CVM: 0.84 (-0.01), CLDX: 20.97 (+0.53), INCY: 75.94 (+0.28), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), DNDN: 0.13 (-0.02), NLNK: 38.84 (+1.51), PPHM: 1.28 (+0.03), BMY: 60.04 (+0.56), FPRX: 24.63 (+0.63)
PUBLICATION IN ACCORDANCE WITH ARTICLE 15 OF THE BELGIAN LAW OF 2 MAY 2007 ON THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW"
GlobeNewswire - Thu Jul 03, 11:07AM CDT
Ablynx [Euronext Brussels: ABLX] announces that the closing of its private placement ("Accelerated Bookbuild Offering"/"ABO"